Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

ALKS
Alkermes Inc. plc
stock NASDAQ

At Close
Jul 11, 2025 3:59:54 PM EDT
30.28USD-0.575%(-0.18)1,483,309
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 9, 2025 8:00:30 AM EDT
29.65USD-2.659%(-0.81)0
After-hours
Jul 11, 2025 4:00:30 PM EDT
30.28USD-0.017%(0.00)2,384
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2022   Benzinga
08:23AM EST  Cantor Fitzgerald Upgrades Alkermes to Overweight, Raises Price Target to $32   Benzinga
Jan 20, 2022
08:28AM EST  The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug   Benzinga
Jan 18, 2022
07:06AM EST  Alkermes To Present Data On Nemvaleukin Alfa At American Society Of Clinical Oncology Gastrointestinal Cancers Symposium Jan. 20   Benzinga
07:03AM EST  Alkermes To Present Data On Nemvaleukin Alfa At American Society Of Clinical Oncology Gastrointestinal Cancers Symposium   RTTNews
07:01AM EST  Alkermes to Present Data on Nemvaleukin Alfa at the American Society of   PR Newswire
Jan 7, 2022
04:00PM EST  Alkermes Option Alert: Jan 21 $29 Calls Sweep (16) near the Ask: 839 @ $0.401 vs 0 OI; Earnings 2/10 Before Open [est] Ref=$24.04   Benzinga
Jan 6, 2022
07:02AM EST  New National Survey of People Living with Bipolar I Disorder Provides Insights   PR Newswire
Jan 5, 2022
04:01PM EST  Alkermes To Take Part In 40th Annual J.P. Morgan Healthcare Conference Jan. 12   Benzinga
04:00PM EST  Alkermes to Take Part in the 40th Annual J.P. Morgan Healthcare Conference   PR Newswire
Dec 1, 2021
10:08AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021   Benzinga
06:47AM EST  Citigroup Initiates Coverage On Alkermes with Neutral Rating, Announces Price Target of $22   Benzinga
Nov 24, 2021
04:13PM EST  Alkermes To Take Part In The Fourth Annual Evercore ISI HealthCONx Conference Dec. 2   Benzinga
04:00PM EST  Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference   PR Newswire
Nov 19, 2021
07:02AM EST  Alkermes Appoints Cato Laurencin To Board   RTTNews
07:01AM EST  Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its   PR Newswire
Nov 11, 2021
07:19AM EST  Alkermes Announces First Subject Dosed In Phase 1 Study Of ALKS 1140 For The Treatment Of Neurodegenerative And Neurological Disorders   Benzinga
07:03AM EST  Alkermes : First Subject Dosed In Phase 1 Study Of ALKS 1140 For Treatment Of Neurodegenerative &Neurological Disorders   RTTNews
07:01AM EST  Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the   PR Newswire
Nov 9, 2021
04:00PM EST  Alkermes to Take Part in the Stifel Virtual Healthcare Conference   PR Newswire
11:42AM EST  The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data   Benzinga
11:24AM EST  SVB Leerink Maintains Market Perform on Alkermes, Lowers Price Target to $24   Benzinga
11:08AM EST  Alkermes Announces Receipt Of Notices Of Partial Termination From Janssen Pharmaceutica In Respect Of Two License Agreements; Says 'The terminations impact know-how royalties related to sales of long-acting paliperidone products'   Benzinga
Nov 8, 2021
04:09PM EST  Alkermes Announces Receipt Of Notices Of Partial Termination From Janssen Pharma   RTTNews
04:05PM EST  Alkermes Announces Receipt of Notices of Partial Termination From Janssen   PR Newswire
Nov 3, 2021
07:02AM EDT  Alkermes to Present Data on Nemvaleukin Alfa at the Society for Immunotherapy   PR Newswire
Oct 29, 2021
07:17AM EDT  Alkermes To Present New Research From Psychiatry And Addiction Portfolios At Upcoming Scientific Conferences   Benzinga
07:01AM EDT  Alkermes to Present New Research From Psychiatry and Addiction Portfolios at   PR Newswire
Oct 28, 2021
07:39AM EDT  10 Biggest Price Target Changes For Thursday   Benzinga
06:33AM EDT  HC Wainwright & Co. Maintains Neutral on Alkermes, Raises Price Target to $30   Benzinga
Oct 27, 2021
07:31AM EDT  Alkermes Q3 EPS $0.14 Beats $0.06 Estimate, Sales $294.14M Miss $301.36M Estimate   Benzinga
07:05AM EDT  Alkermes Q3 Adj. EPS $0.14, Consensus $0.06   RTTNews
07:01AM EDT  Alkermes plc Reports Third Quarter 2021 Financial Results   PR Newswire
03:43AM EDT  Earnings Scheduled For October 27, 2021   Benzinga
Oct 26, 2021
07:08AM EDT  Alkermes Initiates ARTISTRY-7 Phase 3 Trial Of Nemvaleukin Alfa In Patients With Platinum-Resistant Ovarian Cancer   Benzinga
07:02AM EDT  Alkermes Says Initiates ARTISTRY-7 Phase 3 Trial Of Nemvaleukin Alfa In Patients With Platinum-Resistant Ovarian Cancer   RTTNews
07:01AM EDT  Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients   PR Newswire
Oct 25, 2021
07:30AM EDT  Alkermes plc (ALKS) on Monday said it received Fast Track designation from the FDA for its invstigational drug, nemvaleukin alfa, in combination with pembrolizumab, for the treatment of platinum-resistant ovarian cancer.   RTTNews
07:03AM EDT  Alkermes:FDA Grants Fast Track Designation For Nemvaleukin Alfa With Pembrolizumab For Platinum-Resistant Ovarian Cancer   RTTNews
07:03AM EDT  Alkermes Receives FDA Fast Track Designation For Nemvaleukin Alfa In Combination With Pembrolizumab For The Treatment Of Platinum-Resistant Ovarian Cancer   Benzinga
07:01AM EDT  Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer   PR Newswire
Oct 24, 2021
11:45AM EDT  The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More   Benzinga
Oct 20, 2021
04:00PM EDT  Alkermes to Report Third Quarter 2021 Financial Results on Oct. 27, 2021   PR Newswire
Oct 18, 2021
07:16AM EDT  Alkermes Announces Commercial Availability of LYBALVI For The Treatment Of Schizophrenia And Bipolar I Disorder   Benzinga
07:00AM EDT  Alkermes Announces Commercial Availability of LYBALVI(r) for the Treatment of   PR Newswire
Oct 7, 2021
10:32AM EDT  Jefferies Upgrades Alkermes to Buy, Announces $36 Price Target   Benzinga
Sep 29, 2021
08:13AM EDT  The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug   Benzinga
Sep 22, 2021
04:00PM EDT  Alkermes to Take Part in the Cantor Virtual Global Healthcare Conference   PR Newswire
07:01AM EDT  New Survey Provides Insights Into Drinking Behaviors During the Pandemic   PR Newswire
Sep 13, 2021
07:06AM EDT  Alkermes To Present Two Posters On Investigational Immuno-oncology Candidate, Nemvaleukin Alfa, At 2021 European Society For Medical Oncology Virtual Congress   Benzinga
07:05AM EDT  Alkermes To Present Two Posters On Investigational Immuno-oncology Candidate, Nemvaleukin Alfa At ESMO   RTTNews
07:02AM EDT  Nemvaleukin Alfa, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress   PR Newswire
Sep 9, 2021
07:03AM EDT  Alkermes To Begin Accepting Applications For Annual Alkermes Pathways Research Awards Program On Sept. 13   RTTNews
07:01AM EDT  Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards(r)   PR Newswire
Sep 2, 2021
04:00PM EDT  Alkermes to Take Part in the Citi Annual BioPharma Virtual Conference   PR Newswire
11:01AM EDT  BofA Downgrades Alkermes After Stock Rally: 'We Don't See A Favorable Catalyst Pathway'   Benzinga
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021   Benzinga
07:10AM EDT  B of A Securities Downgrades Alkermes to Underperform, Announces $27 Price Target   Benzinga
Sep 1, 2021
07:32AM EDT  The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering   Benzinga
Aug 31, 2021
08:15AM EDT  The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical   Benzinga
Aug 27, 2021
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
Aug 24, 2021
08:09AM EDT  The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 6, 2021
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
Aug 2, 2021
11:18AM EDT  Return on Capital Employed Insights for Alkermes   Benzinga
08:53AM EDT  Alkermes Receives FDA Fast Track Status For Mucosal Melanoma Immunotherapy   Benzinga
07:17AM EDT  Alkermes Gets Fast Track Designation For Nemvaleukin -   RTTNews
07:02AM EDT  Alkermes Receives FDA Fast Track Designation For Nemvaleukin Alfa For Treatment Of Mucosal Melanoma   Benzinga
07:01AM EDT  Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the   PR Newswire
07:01AM EDT  Alkermes Gets FDA Fast Track Designation For Nemvaleukin Alfa For Treatment Of Mucosal Melanoma   RTTNews
Jul 30, 2021
07:54AM EDT  The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs   Benzinga
Jul 29, 2021
10:45AM EDT  Mizuho Maintains Buy on Alkermes, Raises Price Target to $33   Benzinga
08:18AM EDT  The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs   Benzinga
05:40AM EDT  SVB Leerink Maintains Market Perform on Alkermes, Raises Price Target to $25   Benzinga
Jul 28, 2021
07:59AM EDT  While reporting financial results for the second quarter on Wednesday, biopharmaceutical company Alkermes plc (ALKS) raised its earnings and revenue guidance for the full-year 2021, based on the strong first half performance and anticipated continued strength in the business.   RTTNews
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
07:27AM EDT  Alkermes: Q2 Earnings Insights   Benzinga
07:08AM EDT  UPDATE: Alkermes Raises FY21 Guidance: Adj. EPS From $0.37-$0.62 To $0.52-$0.70 vs $0.51 Estimate, Sales From $1.1B-$1.17B To $1.145B-$1.185B vs $1.14B Est.   Benzinga
07:07AM EDT  Alkermes Raises Guidance   Benzinga
07:06AM EDT  Alkermes Q2 Adj. EPS $0.30 Beats $0.12 Estimate, Sales $303.70M Beat $278.70M Estimate   Benzinga
07:03AM EDT  Alkermes Plc Q2 GAAP EPS $0.01 And Non-GAAP EPS $0.30   RTTNews
07:01AM EDT  Alkermes plc Reports Second Quarter 2021 Financial Results   PR Newswire
04:27AM EDT  Earnings Scheduled For July 28, 2021   Benzinga
Jul 25, 2021
10:05AM EDT  The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More   Benzinga
Jul 23, 2021
07:01AM EDT  Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants(r) Program   PR Newswire
Jul 21, 2021
04:01PM EDT  Alkermes to Report Second Quarter 2021 Financial Results on July 28, 2021   PR Newswire
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jul 7, 2021
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jun 30, 2021
07:10AM EDT  Alkermes Presents New Data Analysis On Healthcare Resource Use Among Veterans With Alcohol Dependence At RSA Meeting   RTTNews
07:01AM EDT  Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans   PR Newswire
Jun 22, 2021
07:01AM EDT  Alkermes Announces Former Professional Baseball Player, CC Sabathia, as   PR Newswire
Jun 16, 2021
02:12PM EDT  Alkermes, Anavex Life Sciences ClinicalTrials.gov Study Record Detail For Co.'s 'Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers,' Shows Not Yet Recruiting   Benzinga
02:09PM EDT  Anavex Life Sciences, Alkermes Post Study Titled 'Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers' To ClinicalTrials.Gov Site   Benzinga
Jun 15, 2021
08:07AM EDT  The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda   Benzinga
Jun 11, 2021
08:05AM EDT  The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts   Benzinga
Jun 10, 2021
08:13AM EDT  The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal   Benzinga
Jun 9, 2021
09:14AM EDT  The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US   Benzinga
Jun 8, 2021
09:17AM EDT  The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex   Benzinga
Jun 4, 2021
03:46PM EDT  Alkermes Option Alert: Aug 20 $25 Calls at the Ask: 4900 @ $1.15 vs 7300 OI; Earnings 7/28 Before Open [est] Ref=$23.05   Benzinga
09:20AM EDT  Alkermes Reports New Data From Its ARTISTRY Clinical Development Program For Nemvaleukin Alfa   RTTNews
09:19AM EDT  Alkermes Says Presents New Data On Nemvaleukin Alfa At 2021 ASCO Meeting   Benzinga
09:16AM EDT  Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of   PR Newswire
Jun 3, 2021
06:39PM EDT  Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference   PR Newswire
Jun 2, 2021
06:11AM EDT  HC Wainwright & Co. Maintains Neutral on Alkermes, Raises Price Target to $25   Benzinga
Jun 1, 2021
09:35AM EDT  Alkermes Shares Move Higher On FDA Approval Of Schizophrenia, Bipolar Med   Benzinga
07:05AM EDT  Alkermes Announces FDA Approval Of LYBALVI For Schizophrenia And Bipolar I Disorder   RTTNews
07:02AM EDT  Alkermes Announces FDA Approval Of LYBALVI For Treatment Of Schizophrenia And Bipolar I Disorder   Benzinga
07:01AM EDT  Alkermes Announces FDA Approval of LYBALVI(tm) for the Treatment of   PR Newswire
May 28, 2021
04:01PM EDT  Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting   PR Newswire
May 20, 2021
07:01AM EDT  Alkermes Appoints Emily Peterson Alva To Board   RTTNews
07:01AM EDT  Alkermes Announces the Appointment of Emily Peterson Alva to its Board of   PR Newswire
May 13, 2021
07:03AM EDT  Alkermes To Begin Accepting Applications For Alkermes Inspiration Grants Program Beginning On May 20   RTTNews
07:01AM EDT  Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer   PR Newswire
May 5, 2021
04:00PM EDT  Alkermes to Take Part in the BofA Securities 2021 Virtual Healthcare Conference   PR Newswire
May 3, 2021
07:08AM EDT  Alkermes To Present Clinical Data And Outcomes Research From Psychiatry Portfolio During Mental Health Awareness In May   RTTNews
07:01AM EDT  Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific   PR Newswire
Apr 30, 2021
09:21AM EDT  Alkermes plc (ALKS) said that it has reached an agreement with Sarissa Capital Management LP, a beneficial owner of about 5% of the company's outstanding ordinary shares, by which Sarissa Capital has the right to designate a director to the company's Board of Directors.   RTTNews
07:31AM EDT  The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs   Benzinga
07:03AM EDT  Alkermes Enters Agreement With Sarissa Capital; Grants Sarissa Right To Designate Director To Board   RTTNews
07:01AM EDT  Alkermes Announces Agreement with Sarissa Capital   PR Newswire
Apr 29, 2021
06:35AM EDT  HC Wainwright & Co. Maintains Neutral on Alkermes, Raises Price Target to $24   Benzinga
Apr 28, 2021
07:41AM EDT  Alkermes: Q1 Earnings Insights   Benzinga
07:26AM EDT  The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping   Benzinga
07:17AM EDT  Alkermes Q1 EPS $0.11 Beats $(0.02) Estimate, Sales $251.40M Beat $233.45M Estimate   Benzinga
07:12AM EDT  Alkermes Says Two Abstracts Accepted For Presentation At 2021 American Society Of Clinical Oncology Annual Meeting   RTTNews
07:06AM EDT  Alkermes Plc Q1 GAAP Loss Per Share $0.14 And Non-GAAP EPS Of $0.11   RTTNews
07:05AM EDT  Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American   PR Newswire
07:01AM EDT  Alkermes plc Reports First Quarter 2021 Financial Results   PR Newswire
04:15AM EDT  Earnings Scheduled For April 28, 2021   Benzinga
Apr 27, 2021
04:01PM EDT  Alkermes Launches New Disease State Website to Offer Education About Alcohol   PR Newswire
08:00AM EDT  Alkermes Launches Mid-Stage Melanoma Study Of Nemvaleukin As Monotherapy   Benzinga
07:09AM EDT  Alkermes Announces Initiation Of ARTISTRY-6 Phase 2 Trial   RTTNews
07:08AM EDT  Alkermes Initiates ARTISTRY-6 Trial Of Nemvaleukin Alfa Monotherapy In Patients With Melanoma   Benzinga
07:01AM EDT  Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients   PR Newswire
Apr 24, 2021
09:24AM EDT  The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx   Benzinga
Apr 21, 2021
04:00PM EDT  Alkermes to Host Conference Call to Discuss First Quarter 2021 Financial Results   PR Newswire
Apr 20, 2021
04:02PM EDT  Alkermes Presents New Data From Psychiatry Portfolio At Virtual 2021 Congress Of The Schizophrenia International Research Society   Benzinga
04:01PM EDT  Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress   PR Newswire
Apr 7, 2021
11:58AM EDT  Alkermes shares were trading higher after the company announced a clinical trial agreement with MSD to evaluate Nemvaleukin Alfa in combination with KEYTRUDA in patients with platinum-resistant ovarian cancer.   Benzinga
07:58AM EDT  The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award   Benzinga
07:41AM EDT  Alkermes plc (ALKS) has entered into a clinical trial collaboration and supply agreement with Merck & Co. for a planned phase III study of Alkermes' nemvaleukin alfa in combination with Merck's Keytruda in patients with platinum-resistant ovarian cancer, Alkermes said in a release.   RTTNews
07:07AM EDT  Alkermes Enters Clinical Trial Collaboration And Supply Agreement With Merck   RTTNews
07:03AM EDT  Alkermes Announces Clinical Trial Collaboration And Supply Agreement With MSD To Evaluate Nemvaleukin Alfa In Combination With KEYTRUDA In Patients With Platinum-Resistant Ovarian Cancer   Benzinga
07:03AM EDT  to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA(r) in Patients With Platinum-Resistant Ovarian Cancer   PR Newswire
Mar 25, 2021
04:01PM EDT  Alkermes To Participate In Stifel's 3rd Annual CNS Day Apr. 1 At 8:30 a.m. ET   Benzinga
04:01PM EDT  Alkermes to Take Part in Stifel's 3rd Annual CNS Day   PR Newswire
07:08AM EDT  Alkermes Plans To Provide New Updates And Disclose New Programs In Neuroscience And Oncology Development Pipeline   RTTNews
07:01AM EDT  Alkermes Investor Day to Focus on Scientific Progress and Value Creation   PR Newswire
Mar 11, 2021
08:19AM EST  The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena   Benzinga
07:23AM EST  Alkermes plc (ALKS), a global biopharmaceutical company developing medicines in the fields of neuroscience and oncology, said nemvaleukin alfa, its investigational engineered interleukin-2 variant immunotherapy, has been granted orphan drug designation for the treatment of mucosal melanoma by the FDA.   RTTNews
07:02AM EST  Alkermes Announces FDA Grants Orphan Drug Designation For Nemvaleukin Alfa For Treatment Of Mucosal Melanoma   RTTNews
07:01AM EST  Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for   PR Newswire
07:01AM EST  Alkermes Announces FDA Orphan Drug Designation For Nemvaleukin Alfa For Treatment Of Mucosal Melanoma   Benzinga
Mar 9, 2021
06:38PM EST  Alkermes Received FDA Orphan Drug Designation for fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha for Treatment of mucosal melanoma   Benzinga
Mar 4, 2021
08:02AM EST  Alkermes to Hold Virtual Investor Day   PR Newswire
Feb 18, 2021
04:00PM EST  Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference   PR Newswire
Feb 11, 2021
07:15AM EST  While reporting financial results for the fourth quarter on Thursday, biopharmaceutical company Alkermes plc (ALKS) initiated its earnings and revenue guidance for the full-year 2021. This guidance reflects the anticipated growth of proprietary products and investment in strategic priorities for long-term value creation.   RTTNews
07:02AM EST  Alkermes Plc Q4 Loss Per Share $0.27; Non-GAAP EPS $0.10   RTTNews
07:01AM EST  Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended   PR Newswire
03:51AM EST  Earnings Scheduled For February 11, 2021   Benzinga
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Feb 6, 2021
12:42PM EST  The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight   Benzinga
Feb 4, 2021
04:00PM EST  Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020   PR Newswire
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 14, 2021
07:08AM EST  NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine   Benzinga
07:04AM EST  Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion For Treatment Of MUD Published   RTTNews
07:01AM EST  Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine   PR Newswire
Jan 13, 2021
07:25AM EST  The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations   Benzinga
Jan 6, 2021
04:00PM EST  Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference   PR Newswire
07:30AM EST  Alkermes Announces Blair C. Jackson Has Been Appointed Chief Operating Officer And Iain M. Brown Will Assume The Role Of Chief Financial Officer   Benzinga
07:09AM EST  Alkermes plc (ALKS) has appointed Blair Jackson chief operating officer. Jackson will expand his current role as senior vice president of corporate planning to become executive vice president and COO, a newly created role which will oversee global operations, quality, finance, information technology, and corporate planning.   RTTNews
07:03AM EST  Alkermes Names Blair Jackson COO And Iain Brown CFO   RTTNews
07:01AM EST  Alkermes Announces Updates to Executive Leadership Team   PR Newswire
Dec 29, 2020
11:24AM EST  Alkermes shares were trading higher after the FDA accepted the company's resubmission of its New Drug Application for ALKS 3831.   Benzinga
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
07:10AM EST  Alkermes: FDA Sets PDUFA Action Date Of June 1 For ALKS   RTTNews
07:03AM EST  FDA Accepts Alkermes' Resubmission Of New Drug Application For ALKS 3831   Benzinga
07:02AM EST  FDA Accepts Alkermes' Resubmission Of NDA For ALKS 3831; FDA Sets PDUFA Target Action Date Of June 1, 2021   RTTNews
07:01AM EST  FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831   PR Newswire
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 11, 2020
05:13AM EST  SVB Leerink Maintains Market Perform on Alkermes, Raises Price Target to $23   Benzinga
Dec 10, 2020
07:42AM EST  Alkermes To Implement Value Enhancement Plan; Announces   RTTNews
07:06AM EST  Alkermes Announces Strategic Value Enhancement Plan And Continued Board Refreshment; New Committee Will Evaluate Strategic Options Related To Non-Core Assets   Benzinga
07:02AM EST  Alkermes Announces Profitability Targets & Cost Structure Optimization Efforts   RTTNews
07:01AM EST  Alkermes Announces Strategic Value Enhancement Plan and Continued Board   PR Newswire
Nov 28, 2020
01:08PM EST  Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates   Benzinga
Nov 17, 2020
08:32AM EST  The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration   Benzinga
07:25AM EST  Alkermes plc (ALKS) said Tuesday that it received a complete response letter from the U.S. Food and Drug Administration regarding its New Drug Application for ALKS 3831 or olanzapine/samidorphan for the treatment of adults with schizophrenia and adults with bipolar I disorder.   RTTNews
07:06AM EST  Alkermes Receives FDA CRL For ALKS 3831 For Adults With Schizophrenia And Adults With Bipolar I Disorder   RTTNews
07:05AM EST  UPDATE: Alkermes Says FDA Stated Resolution Of Certain Conditions Related To The Tablet Coating Process At The Company's Wilmington Facility Is Required Before ALKS 3831 May Be Approved; CRL Did Not Identify Concerns About Clinical Or Non-Clinical Data   Benzinga
07:04AM EST  Alkermes Receives FDA Complete Response Letter Related To ALKS 3831 Manufacturing Records Review   Benzinga
07:01AM EST  Alkermes Receives FDA Complete Response Letter Related to ALKS 3831   PR Newswire
Nov 9, 2020
09:17AM EST  Alkermes Highlights Presentation Of New Data On ALKS 4230 At Society For Immunotherapy Of Cancer Meeting Nov. 11-14: 'Subcutaneous Dosing of ALKS 4230 in ARTISTRY-2 Showed Desired Immune Response and Safety Profile Consistent With the Observed Effects...'   Benzinga
08:03AM EST  Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of   PR Newswire
Nov 3, 2020
08:05AM EST  Alkermes Pharma Ireland Limited Granted Patent by USPTO Number 10,822,306 Dated November 3, 2020 Titled 'Heterocyclic compounds for the treatment of neurological and psychological disorders'   Benzinga
Oct 29, 2020
10:25AM EDT  Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to   PR Newswire
08:00AM EDT  Alkermes Q3 EPS $0.26 Up From $(0.04) YoY, Sales $265.01M Beat $238.39M Estimate   Benzinga
07:30AM EDT  The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal   Benzinga
07:02AM EDT  Alkermes Plc Reports Q3 Breakeven Per Share; Non-GAAP EPS Of $0.26   RTTNews
07:01AM EDT  Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020   PR Newswire
04:08AM EDT  Earnings Scheduled For October 29, 2020   Benzinga
Oct 28, 2020
06:06PM EDT  Notable Earnings Watchlist For Thursday, Oct. 29, 2020 Before Market Open: PCG, NOK, OSTK, KHC, SNY, RCL, K, RL, COHU, CMCSA, ABEV, ALXN, CS, TXT, XYL, YUM, TPR, TAP, SPOT, COP, ALKS, AAN, BAX, TPX, KDP, NEM, BC, APRN, BWA, DNKN, DD, HUN, TAK, BUD   Benzinga
Oct 22, 2020
04:01PM EDT  Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results   PR Newswire
Oct 15, 2020
09:54AM EDT  Mizuho Upgrades Alkermes to Buy, Raises Price Target to $24   Benzinga
Oct 9, 2020
05:12PM EDT  FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of   PR Newswire
07:06AM EDT  Alkermes Says Nasdaq Halts Trading Of Company's Ordinary Shares   RTTNews
07:05AM EDT  Trading in Alkermes Ordinary Shares Halted Today   PR Newswire
Oct 7, 2020
10:16AM EDT  Alkermes Announces Posting Of Briefing Documents For FDA Advisory Committee Meeting On ALKS 3831   RTTNews
10:15AM EDT  Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee   PR Newswire
10:15AM EDT  Alkermes Posts Briefing Docs For FDA AdCom Meeting On ALKS 3831   Benzinga
Oct 6, 2020
08:11AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Oct. 6, 2020: DPZ, AZYO, OGEN, ALKS, AN   Benzinga
Sep 30, 2020
10:56AM EDT  B of A Securities Maintains Neutral on Alkermes, Lowers Price Target to $19   Benzinga
Sep 18, 2020
06:54AM EDT  Alkermes Presents New Clinical Data On ALKS 4230 In Mini Oral Presentation At 2020 ESMO Virtual Congress   RTTNews
06:31AM EDT  Alkermes Will Present New Clinical Data On ALKS 4230 For IL-2 Variant Immunotherapy At European Society For Medical Oncology Sept. 18   Benzinga
06:30AM EDT  Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at   PR Newswire
Sep 14, 2020
07:02AM EDT  Alkermes Presents New Psychiatry Data At Psych Congress 2020 Virtual Experience   RTTNews
Sep 9, 2020
04:00PM EDT  Alkermes to Take Part in Cantor Virtual Global Healthcare Conference   PR Newswire
Sep 8, 2020
07:06AM EDT  Alkermes To Present New Data On Investigational Immuno-Oncology Candidate, ALKS 4230, At 2020 European Society For Medical Oncology (ESMO) Virtual Congress   Benzinga
07:01AM EDT  Alkermes to Present New Data on Investigational Immuno-Oncology Candidate, ALKS   PR Newswire
Aug 21, 2020
07:03AM EDT  FDA Advisory Committee Meeting To Review ALKS 3831 NDA Tentatively Scheduled For Oct. 9, 2020   RTTNews
07:01AM EDT  Virtual FDA Advisory Committee Meeting To Review New Drug Application For ALKS 3831 For Treatment Of Schizophrenia And Bipolar I Disorder Tentatively Scheduled For Oct. 9, 2020   Benzinga
07:00AM EDT  3831 for Treatment of Schizophrenia and Bipolar I Disorder Tentatively Scheduled for Oct. 9, 2020   PR Newswire
Aug 19, 2020
07:13AM EDT  Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors   Benzinga
07:01AM EDT  Alkermes Begins Phase 2 Study To Evaluate Clinical And Immunologic Activity Of ALKS 4230 In Advanced Solid Tumors   RTTNews
07:01AM EDT  Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors   PR Newswire
Aug 17, 2020
07:05AM EDT  American Journal Of Psychiatry Publishes Data From Alkermes' Phase 3 ENLIGHTEN-2 Weight Study Of ALKS 3831   RTTNews
07:04AM EDT  Alkermes' Data From the Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia is Published in the American Journal of Psychiatry; Data Was First Reported in November 2018   Benzinga
07:01AM EDT  American Journal of Psychiatry Publishes Data From Alkermes' Phase 3   PR Newswire
Jul 29, 2020
10:27AM EDT  Alkermes shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. UPDATE: Shares have since reversed.   Benzinga
07:41AM EDT  Alkermes: Q2 Earnings Insights   Benzinga
07:20AM EDT  While reporting financial results for the second quarter on Wednesday, biopharmaceutical company Alkermes plc (ALKS) re-initiated its earnings and revenue guidance for the full-year 2020. This guidance reflects the anticipated net impacts of the COVID-19 pandemic on Alkermes' operating and financial results.   RTTNews
07:07AM EDT  Alkermes Sees FY20 Adj. EPS $0.00$0.19, Sakes $965M-$1.005B vs $983.04M Est.   Benzinga
07:06AM EDT  Alkermes Q2 Adj. EPS $0.06 Beats $(0.01) Estimate, Sales $247.53M Beat $232.75M Estimate   Benzinga
07:05AM EDT  Alkermes Q2 GAAP Net Loss Per Share $0.19 Vs Loss $0.27 Last Year   RTTNews
07:01AM EDT  Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020   PR Newswire
04:04AM EDT  Earnings Scheduled For July 29, 2020   Benzinga
Jul 22, 2020
04:00PM EDT  Alkermes to Host Conference Call to Discuss Second Quarter 2020 Financial   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC